This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (140)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Clinical and Laboratory Characteristics Associated With Improvement

P. A. van Doom, MD; M. Vermeulen, MD; A. Brand, MD; P. G. H. Mulder, PhD; H. F. M. Busch, MD

Arch Neurol. 1991;48(2):217-220.

Abstract
• Of 52 patients fulfilling the criteria of chronic inflammatory demyelinating polyneuropathy, 20 (38%) did not improve after intravenous immunoglobulin treatment, two (4%) had a short-lasting improvement and subsequent infusions had no effect, nine (17%) reached a spontaneously or therapeutically induced complete remission, and 21 patients (40%) needed intermittent infusions to maintain improvement. All patients who improved initially had symptoms that significantly interfered with life-style. After treatment, 90% of these patients were independent in their daily activities. Significantly associated with improvement were disease duration of less than 1 year, progression of weakness until treatment, absence of discrepancy in weakness between arms and legs, areflexia of the arms, and slowed nerve conduction velocity of the motor median nerve. The probability of improvement if all these features are present is 93%.

Author Affiliations
From the Department of Neurology, University Hospital Dijkzigt, Rotterdam (Drs van Doom, Vermeulen, and Busch); the Department of Immunohematology and Bloodbank, University Hospital, Leiden (Dr Brand); and the Department of Biostatistics, Erasmus University, Rotterdam (Dr Mulder), the Netherlands.

Footnotes
Accepted for publication May 11, 1990.

Reprint requests to Department of Neurology, University Hospital Dijkzigt, Dr Molewaterplein 40, 3015 GD Rotterdam, the Netherlands (Dr van Doom).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Clinical and electrophysiologic correlates of IVIg responsiveness in CIDP
Iijima et al.
Neurology 2005;64:1471-1475.
ABSTRACT | FULL TEXT  

Immunoglobulins inhibit pathophysiological effects of anti-GQ1b-positive sera at motor nerve terminals through inhibition of antibody binding
Jacobs et al.
Brain 2003;126:2220-2234.
ABSTRACT | FULL TEXT  

Current treatments for CIDP
Ropper
Neurology 2003;60:S16-22.
ABSTRACT | FULL TEXT  

Intravenous gammaglobulin (IVIg) for treatment of CIDP and related immune-mediated neuropathies
Brannagan
Neurology 2002;59:S33-40.
ABSTRACT | FULL TEXT  

Quality of life complements traditional outcome measures in immune-mediated polyneuropathies
Merkies et al.
Neurology 2002;59:84-91.
ABSTRACT | FULL TEXT  

Immunoglobulin therapy for idiopathic chronic sensory ataxic neuropathy
Takeuchi et al.
Neurology 2000;54:1008-1010.
FULL TEXT  

Intravenous Immunoglobulin Treatment in Neurologic Disorders: Yes
Sorensen
Arch Neurol 1999;56:1025-1027.
FULL TEXT  

A unique population of circulating autoantibodies promotes central nervous system remyelination
Asakura and Rodriguez
Mult Scler 1998;4:217-221.
ABSTRACT  

Intravenous immunoglobulin treatment in multifocal motor neuropathy and other chronic immune-mediated neuropathies
Comi et al.
Mult Scler 1997;3:93-97.
ABSTRACT  

Immunomodulation and remyelination: two aspects of human polyclonal immunoglobulin treatment in immune mediated neuropathies?
van Schaik et al.
Mult Scler 1997;3:98-104.
ABSTRACT  

Acute Renal Failure Resulting From Intravenous Immunoglobulin Therapy
Tan et al.
Arch Neurol 1993;50:137-139.
ABSTRACT  

Chronic Inflammatory Demyelinating Polyneuropathy: Immunoglobulins or Plasmapheresis?
Prick and Verhagen
Arch Neurol 1991;48:1118-1119.
ABSTRACT